As of 2026-07-20, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -49.97. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 579.60 mil USD. MYGN's TTM EBITDA according to its financial statements is -11.60 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 9.4x - 15.9x | 12.7x |
| Forward P/E multiples | 9.7x - 16.1x | 13.1x |
| Fair Price | (1.15) - (1.91) | (1.54) |
| Upside | -118.7% - -130.9% | -124.9% |
| Date | EV/EBITDA |
| 2026-07-17 | -49.97 |
| 2026-07-16 | -50.05 |
| 2026-07-15 | -51.02 |
| 2026-07-14 | -48.83 |
| 2026-07-13 | -47.36 |
| 2026-07-10 | -47.12 |
| 2026-07-09 | -49.31 |
| 2026-07-08 | -47.44 |
| 2026-07-07 | -47.36 |
| 2026-07-06 | -48.74 |
| 2026-07-02 | -48.42 |
| 2026-07-01 | -48.50 |
| 2026-06-30 | -46.14 |
| 2026-06-29 | -47.28 |
| 2026-06-26 | -47.52 |
| 2026-06-25 | -43.86 |
| 2026-06-24 | -42.15 |
| 2026-06-23 | -37.35 |
| 2026-06-22 | -36.29 |
| 2026-06-18 | -36.61 |
| 2026-06-17 | -35.31 |
| 2026-06-16 | -34.25 |
| 2026-06-15 | -34.82 |
| 2026-06-12 | -34.90 |
| 2026-06-11 | -37.35 |
| 2026-06-10 | -35.72 |
| 2026-06-09 | -36.61 |
| 2026-06-08 | -35.39 |
| 2026-06-05 | -36.86 |
| 2026-06-04 | -37.83 |
| 2026-06-03 | -35.47 |
| 2026-06-02 | -34.74 |
| 2026-06-01 | -34.50 |
| 2026-05-29 | -31.97 |
| 2026-05-28 | -34.01 |
| 2026-05-27 | -31.65 |
| 2026-05-26 | -30.99 |
| 2026-05-22 | -30.75 |
| 2026-05-21 | -31.48 |
| 2026-05-20 | -30.67 |
| 2026-05-19 | -28.55 |
| 2026-05-18 | -29.37 |
| 2026-05-15 | -28.80 |
| 2026-05-14 | -29.12 |
| 2026-05-13 | -30.02 |
| 2026-05-12 | -32.79 |
| 2026-05-11 | -33.93 |
| 2026-05-08 | -34.58 |
| 2026-05-07 | -32.95 |
| 2026-05-06 | -33.11 |